Literature DB >> 9326638

Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.

E Z Wolpert1, M Petersson, B J Chambers, J K Sandberg, R Kiessling, H G Ljunggren, K Kärre.   

Abstract

Cells with impaired transporter associated with antigen processing (TAP) function express low levels of cell surface major histocompatibility complex (MHC) class I molecules, and are generally resistant to lysis by MHC class I restricted cytotoxic T lymphocytes (CTLs). Here we report the generation of MHC class I restricted CD8(+) CTLs that surprisingly require target cell TAP deficiency for efficient recognition. C57BL/6 (B6) mice immunized with syngenic B7-1 (CD80) expressing TAP-deficient cells generated a potent CTL response against both TAP-deficient RMA-S tumor cells and TAP-deficient Con A blasts, whereas the corresponding TAP-expressing target cells were considerably less susceptible or resistant to lysis. The CTL epitopes recognized were expressed also by the human TAP-deficient cell line T2, transfected with appropriate MHC class I molecules. B6 mice immunized with B7-1-transfected TAP-deficient RMA-S cells were protected from outgrowth of a subsequent RMA-S tumor challenge. These findings are discussed in relation to the biochemical nature of MHC class I dependent CTL epitopes associated with impaired TAP function, as well as implications for immunotherapy and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326638      PMCID: PMC23517          DOI: 10.1073/pnas.94.21.11496

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

Review 1.  Peptide antigen production by the proteasome: complexity provides efficiency.

Authors:  M Groettrup; A Soza; U Kuckelkorn; P M Kloetzel
Journal:  Immunol Today       Date:  1996-09

Review 2.  TAP off--tumors on.

Authors:  B Seliger; M J Maeurer; S Ferrone
Journal:  Immunol Today       Date:  1997-06

3.  MHC class I molecules form ternary complexes with calnexin and TAP and undergo peptide-regulated interaction with TAP via their extracellular domains.

Authors:  W K Suh; E K Mitchell; Y Yang; P A Peterson; G L Waneck; D B Williams
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

4.  Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells.

Authors:  L Franksson; M Petersson; R Kiessling; K Kärre
Journal:  Eur J Immunol       Date:  1993-10       Impact factor: 5.532

5.  MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.

Authors:  H G Ljunggren; L Van Kaer; M S Sabatine; H Auchincloss; S Tonegawa; H L Ploegh
Journal:  Int Immunol       Date:  1995-06       Impact factor: 4.823

6.  Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo.

Authors:  S K Nair; D Snyder; E Gilboa
Journal:  J Immunol       Date:  1996-03-01       Impact factor: 5.422

7.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

8.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

9.  Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

Authors:  A Y Huang; A T Bruce; D M Pardoll; H I Levitsky
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.

Authors:  J V Johnston; A R Malacko; M T Mizuno; P McGowan; I Hellström; K E Hellström; H Marquardt; L Chen
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  13 in total

1.  TAP-ing into TIEPPs for cancer immunotherapy.

Authors:  Rolf Kiessling
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

Review 2.  Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Authors:  Ian Mantel; Barzan A Sadiq; J Magarian Blander
Journal:  Mol Immunol       Date:  2021-12-29       Impact factor: 4.174

3.  Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming.

Authors:  Xiao-Lin Li; Dongqing Zhang; David Knight; Yoshinobu Odaka; Jonathan Glass; J Michael Mathis; Qian-Jin Zhang
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

4.  Donor major histocompatibility complex class I expression determines the outcome of prenatal transplantation.

Authors:  Emily T Durkin; Kelly A Jones; Dina Elnaggar; Aimen F Shaaban
Journal:  J Pediatr Surg       Date:  2008-06       Impact factor: 2.545

Review 5.  A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.

Authors:  Ursula J E Seidel; Claudia C Oliveira; Margit H Lampen; Thorbald van Hall
Journal:  Cancer Immunol Immunother       Date:  2011-11-25       Impact factor: 6.968

Review 6.  Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome.

Authors:  Cláudia C Oliveira; Thorbald van Hall
Journal:  Front Immunol       Date:  2015-06-05       Impact factor: 7.561

7.  Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phase.

Authors:  Xiao-Lin Li; Marjolein Sluijter; Elien M Doorduijn; Shubha P Kale; Harris McFerrin; Yong-Yu Liu; Yan Li; Madhusoodanan Mottamal; Xin Yao; Fengkun Du; Baihan Gu; Kim Hoang; Yen H Nguyen; Nichelle Taylor; Chelsea R Stephens; Thorbald van Hall; Qian-Jin Zhang
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

8.  Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.

Authors:  Xiao-Lin Li; Yong-Yu Liu; David Knight; Yoshinobu Odaka; J Michael Mathis; Runhua Shi; Jonathan Glass; Qian-Jin Zhang
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

9.  Qa-1b Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing.

Authors:  Xiao Zhang; Erich Sabio; Chirag Krishna; Xiaoxiao Ma; Jingming Wang; Hui Jiang; Jonathan J Havel; Timothy A Chan
Journal:  Mol Cancer Res       Date:  2021-03-05       Impact factor: 5.852

Review 10.  HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.

Authors:  Per Anderson; Natalia Aptsiauri; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Cell Mol Immunol       Date:  2021-01-20       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.